This analysis showed that, compared to normal tissues, MFAP2 expression was higher in bladder cancer, brain and central nervous system (CNS) cancer, breast cancer, colorectal cancer, esophageal cancer, gastric cancer, head and neck cancer, lymphoma, melanoma, myeloma, ovarian cancer, pancreatic cancer, and sarcoma. This evidence concerns the gene MFAP2 and colorectal cancer.